ACTRIMS: Americas Committee for Treatment and Research in Multiple Sclerosis
Conference Coverage
MS Treatment Decisions Based on Milestones That Matter
PARIS—Tracking disease impact in patients with multiple sclerosis (MS) by predictable loss of economically important milestones...
Conference Coverage
Durable Improvements in Clinical Outcomes With Alemtuzumab: Seven-Year Follow-Up
PARIS—Clinical efficacy of alemtuzumab was maintained for seven years in patients who had inadequate response to prior therapy,...
Conference Coverage
The Expanded Timed Get Up and Go Test Predicts MS Disability
PARIS—The Expanded Timed Get Up and Go (ETGUG) may be a more sensitive predictor of disability in multiple sclerosis (MS) than...
Conference Coverage
Long-Term Outcomes of Neuromyelitis Optica
PARIS—Among patients with neuromyelitis optica (NMO), early disability predicts late disability, consistent with favorable...
Conference Coverage
What Is the Prevalence of Truly Benign MS?
PARIS—Benign multiple sclerosis (MS) appears to be rare. Its estimated prevalence is less than 4%, according to a study described...
Conference Coverage
Oligoclonal Bands Could Be a Valuable Criterion for the Diagnosis of MS
PARIS—Oligoclonal bands, together with symptomatic lesions disseminated in space, increase the risk of multiple sclerosis (MS),...
Conference Coverage
DMTs Reduce the Risk of Conversion to Secondary Progressive MS
PARIS—Secondary progressive multiple sclerosis (MS) is at least partly a consequence of early inflammation, and the risk of...
Conference Coverage
The Diagnostic Value of 2010 McDonald Criteria Versus 2016 MAGNIMS Guidelines for Special MS Populations
PARIS—When faced with patients with clinically isolated syndrome (CIS) or primary progressive multiple sclerosis (PPMS),...
Conference Coverage
Can McArdle’s Sign Help Diagnose MS?
PARIS—McArdle’s sign, a rapidly reversible motor weakness induced by head flexion in patients with suspected multiple sclerosis (...
Conference Coverage
Serum Neurofilament Light Levels May Reflect the Efficacy of MS Treatments
PARIS—It is possible to gauge the effects of disease-modifying therapies (DMTs) for multiple sclerosis (MS) by measuring serum...
Conference Coverage
Can a Saliva Test Provide a New Biomarker for MS?
PARIS—A non-invasive test that assesses immunoglobulin free light chains in saliva may detect immunopathologic changes in the...
Conference Coverage
Evidence builds for mesenchymal stem cell therapy in MS
Repeated intrathecal administration of autologous mesenchymal bone marrow–derived stromal stem cells for the treatment of multiple sclerosis was...
Conference Coverage
BENEFIT 11: No new safety signals with interferon beta-1b
The long-term safety of interferon beta-1b for the treatment of multiple sclerosis is well established, and 11-year outcomes from the randomized,...
Conference Coverage
Study examines efficacy of small group programs for fatigue in MS
Fatigue: Take Control (FTC), a 6-week group education and behavioral program widely used to address fatigue in patients with multiple sclerosis,...